Study of Relugolix Alone and Relugolix Combined With Hormonal Add-Back Therapy in Healthy Premenopausal Female Participants
Status:
Completed
Trial end date:
2016-09-21
Target enrollment:
Participant gender:
Summary
This was a randomized, open-label, repeat dose study of once daily relugolix alone or
relugolix combined with hormonal add-back therapy (combination estradiol/norethindrone
acetate) (E2/NETA) to assess safety, including markers of bone resorption, pharmacokinetics
(PK), and pharmacodynamics (PD) endpoints.